文献速递胸部肿瘤

组织学类型是肺部立体定向放疗疗效的基础

A Histologic Basis for the Efficacy of SBRT to the lung.
PubMed 文献 · J Thorac Oncol · 2016-12-22

该研究分析了2003至2015年接受立体定向体部放疗(SBRT)根治的740例早期非小细胞肺癌(NSCLC)患者,采用竞争风险模型计算局部失败累积发生率,并用Fine和Gray回归分析预测因素。结果显示,鳞癌组织学亚型是局部失败的最强预测因素(风险比=2.4,P=0.008),鳞癌患者3年局部失败累积发生率为18.9%,腺癌为8.7%,NSCLC未另作分类为4.1%。结论认为鳞癌患者SBRT后局部失败率升高,标准放疗方案对不同组织学类型的疗效可能存在差异。

要点

  • 鳞癌组织学亚型是SBRT后局部失败的最强预测因素(风险比=2.4,P=0.008)。
  • 鳞癌患者3年局部失败累积发生率为18.9%(95%CI:12.7-25.1),腺癌为8.7%(95%CI:4.6-12.8),NSCLC未另作分类为4.1%(95%CI:0-9.6)。
  • 总体740例患者中72例出现局部失败,3年局部失败累积发生率为11.8%。

核心结论

  • 研究结果显示鳞状细胞癌患者的局部失败率升高,标准放疗方案对群体有效但可能无法为个体患者实现最佳结果。
  • 明确SBRT在不同组织学类型间的差异剂量效应有可能提高疗效,并为旨在扩展SBRT适应证的正在进行和未来研究提供信息。

研究设计与样本

  • 研究分析了2003年至2015年间接受SBRT根治性治疗的740例早期NSCLC患者。
  • 采用竞争风险方法计算累积发生率曲线,并使用Fine和Gray回归识别局部失败的预测因素。

主要发现

  • 总体有72例患者出现局部失败,3年局部失败累积发生率为11.8%。
  • 单因素分析中,鳞癌组织学亚型、较年轻年龄、较少医学合并症、较高体重指数、较高正电子发射断层扫描标准化摄取值、中央型肿瘤和较低放疗剂量与局部失败风险增加相关。
  • 多因素分析中,鳞癌组织学亚型是局部失败的最强预测因素(风险比=2.4,P=0.008)。
  • 鳞癌患者SBRT后局部失败率显著高于腺癌或NSCLC未另作分类患者,3年局部失败累积发生率分别为18.9%(95%CI:12.7-25.1)、8.7%(95%CI:4.6-12.8)和4.1%(95%CI:0-9.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) is the standard of care for medically inoperable patients with early-stage NSCLC. However, NSCLC is composed of several histological subtypes and the impact of this heterogeneity on SBRT treatments has yet to be established. METHODS: We analyzed 740 patients with early-stage NSCLC treated definitively with SBRT from 2003 through 2015. We calculated cumulative incidence curves using the competing risk method and identified predictors of local failure using Fine and Gray regression. RESULTS: Overall, 72 patients had a local failure, with a cumulative incidence of local failure at 3 years of 11.8%. On univariate analysis, squamous histological subtype, younger age, fewer medical comorbidities, higher body mass index, higher positron emission tomography standardized uptake value, central tumors, and lower radiation dose were associated with an increased risk for local failure. On multivariable analysis, squamous histological subtype (hazard ratio = 2.4 p = 0.008) was the strongest predictor of local failure. Patients with squamous cancers fail SBRT at a significantly higher rate than do those with adenocarcinomas or NSCLC not otherwise specified, with 3-year cumulative rates of local failure of 18.9% (95% confidence interval [CI]: 12.7-25.1), 8.7% (95% CI: 4.6-12.8), and 4.1% (95% CI: 0-9.6), respectively. CONCLUSION: Our results demonstrate an increased rate of local failure in patients with squamous cell carcinoma. Standard approaches for radiotherapy that demonstrate efficacy for a population may not achieve optimal results for individual patients. Establishing the differential dose effect of SBRT across histological groups is likely to improve efficacy and inform ongoing and future studies that aim to expand indications for SBRT.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Woody NM, Stephans KL, Andrews M, et al. A Histologic Basis for the Efficacy of SBRT to the lung. J Thorac Oncol. 2016. PMID: 28017592. doi:10.1016/j.jtho.2016.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。